Welcome to our dedicated page for SciSparc Ltd. Ordinary Shares news (Ticker: SPRC), a resource for investors and traders seeking the latest updates and insights on SciSparc Ltd. Ordinary Shares stock.
SciSparc Ltd. (Nasdaq: SPRC) is a specialty clinical-stage pharmaceutical company dedicated to developing innovative therapies for disorders of the central nervous system. With a strong focus on cannabinoid pharmaceuticals, the company is engaged in pioneering drug development programs targeting conditions like Tourette Syndrome, Alzheimer's disease, pain, Autism Spectrum Disorder (ASD), and status epilepticus using both THC and non-psychoactive CBD.
The company's robust pipeline includes SCI-110 for treating Tourette Syndrome and Alzheimer's agitation, SCI-160 for pain management, and SCI-210 for ASD and status epilepticus. Recently, SciSparc enrolled the first patient in its clinical trial for SCI-210, aimed at treating children with ASD.
In addition to drug development, SciSparc owns a subsidiary focused on online sales of hemp-based wellness products, including gummies, oils, capsules, and creams.
SciSparc's commitment to scientific excellence is highlighted by its collaborations and partnerships. For example, its venture with MitoCareX Bio leverages advanced computational platforms for cancer drug discovery, targeting mitochondrial SLC25 proteins.
The company is also actively expanding its intellectual property portfolio, with recent patents granted in the U.S., Canada, and Europe. These patents cover innovative compositions that enhance the therapeutic effects of cannabinoids while reducing side effects, thereby boosting its competitive edge globally.
Latest News:
- March 8, 2024: First patient enrolled in ASD clinical trial for SCI-210.
- March 12, 2024: MitoCareX Bio screens millions of small molecules for potential anti-cancer treatments.
- March 14, 2024: First patient dosed in SCI-210 ASD trial.
- March 18, 2024: Granted Canadian patent for cannabinoid and n-acylethanolamine compositions.
- March 27, 2024: Clearmind partnership leads to multiple new patent applications.
- May 31, 2024: European Patent Office grants patent for antimicrobial compositions.
Rhea-AI Summary
SciSparc Ltd. (Nasdaq: SPRC) announced successful results from a pre-clinical trial for its obesity and metabolic disorder program in collaboration with Clearmind Medicine Inc. (Nasdaq: CMND). The trial focused on identifying the optimal dosage for the Combination Treatment, which includes palmitoylethanolamide (PEA) and MEAI, resulting in increased metabolic activity, reduced appetite, and enhanced fat oxidation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.92%
Tags
-
Rhea-AI Summary
SciSparc Ltd. (SPRC) adopts a limited duration shareholder rights plan to protect the long-term interests of shareholders and enable them to realize the full potential value of their investment. The plan is designed to reduce the likelihood of any entity gaining control of the company without appropriately compensating all shareholders. The company's CEO, Oz Adler, emphasized the positive results from the weight loss and metabolic disorder program with a proprietary psychedelic-based treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.22%
Tags
-
Rhea-AI Summary
SciSparc Ltd. (SPRC) announces successful results from a pre-clinical trial conducted in collaboration with Clearmind Medicine Inc. The trial focused on the combined treatment of SciSparc's proprietary CannAmide™ and Clearmind Medicine's MEAI molecule, showing promising results for addressing obesity and related health challenges.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.22%
Tags
Rhea-AI Summary
SciSparc Ltd. (SPRC) announces that its joint venture, MitoCareX Bio, has achieved its second milestone by developing laboratory capabilities for cancer drug discovery. The joint venture focuses on targeting the nuclear encoded human mitochondrial carriers, with 53 members found to be altered in various malignancies. The achievement triggers an additional investment of $600,000 from SciSparc, resulting in the company holding 50.1% of MitoCareX Bio's share capital.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.39%
Tags
-
Rhea-AI Summary
SciSparc Ltd. (SPRC) has initiated a clinical trial using its proprietary therapy, SCI-210, at Soroka Medical Center, Israel, targeting Autism Spectrum Disorder (ASD) symptoms in children. The trial will enroll 60 participants between the ages of 5-18 years old to measure how SCI-210 compares to standard CBD treatment in managing ASD symptoms. The trial is structured as a randomized, double-blind, placebo-controlled trial. SciSparc aims to reduce and alleviate the symptoms of autism with its pioneering treatment, partnering with the Soroka Medical Center and the National Autism Research Center to explore new territory in ASD treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
35.22%
Tags
-
News
Rhea-AI Summary
SciSparc Ltd. (SPRC) is considering merging with a leading vehicle importer in Israel, transferring its pharmaceutical activities to a separate legal entity, and exploring the possibility of dividend distribution. The merger is expected to result in the Target Company becoming a wholly-owned subsidiary of SciSparc, and the combined company will continue to trade on the Nasdaq Capital Market under a new name. The Target Company's equity holders will hold approximately 80% of the Combined Company's share capital after the closing.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.8%
Tags
Rhea-AI Summary
SciSparc Ltd. (NASDAQ: SPRC) unveiled positive topline results from its Phase IIa trial at the Sophie & Abraham Stuchynski Israeli Alzheimer’s Medical Center, indicating that its proprietary SCI-110 provided a safe and effective solution for alleviating agitation in elderly Alzheimer's patients. The trial showed a significant 23% reduction in agitation symptoms and a decline in eating and feeding difficulties, demonstrating the potential of SCI-110 in improving the lives of AD patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
48.17%
Tags
-
Rhea-AI Summary
SciSparc Ltd. (Nasdaq: SPRC) initiates Phase IIb clinical trial for its proprietary drug candidate SCI-110 to treat Tourette Syndrome at Yale University, Tel Aviv Sourasky Medical Center, and Hannover Medical School. The trial aims to evaluate the efficacy, safety, and tolerability of SCI-110 in adult patients using a daily oral treatment. Results from the Phase IIA trial at Yale University showed an average tic reduction of 21% and positive tolerability.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.52%
Tags
-
Rhea-AI Summary
SciSparc Ltd. has received notice of acceptance for its patent application for Combination of Opioids and N-Acylethanolamines for pain treatment. The patent has been granted by IP Australia. The global opioid market size was valued at $22.8 billion in 2022 and is expected to grow at a CAGR of 1.4% from 2023 to 2030. SciSparc's growing number of granted patents showcases the innovation in the company's pipeline.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
64.81%
Tags
Rhea-AI Summary
SciSparc receives acceptance for patent application in Australia for Combinations of Cannabinoids and N-Acylethanolamines. The patent strengthens the company's position in the cannabis sector and aligns with its core technologies to enhance the safety and therapeutic benefits of cannabinoids.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.72%
Tags
FAQ
What is the current stock price of SciSparc Ltd. Ordinary Shares (SPRC)?
The current stock price of SciSparc Ltd. Ordinary Shares (SPRC) is $0.2133 as of December 20, 2024.
What is the market cap of SciSparc Ltd. Ordinary Shares (SPRC)?
The market cap of SciSparc Ltd. Ordinary Shares (SPRC) is approximately 2.2M.
What does SciSparc Ltd. do?
SciSparc Ltd. is a clinical-stage pharmaceutical company focused on developing cannabinoid-based therapies for central nervous system disorders.
What are SciSparc's main drug development programs?
SciSparc's main programs include SCI-110 for Tourette Syndrome and Alzheimer's agitation, SCI-160 for pain, and SCI-210 for ASD and status epilepticus.
What recent achievements has SciSparc announced?
Recent achievements include enrolling the first patient in the SCI-210 ASD trial, obtaining a Canadian patent, and expanding partnerships with MitoCareX Bio and Clearmind.
What products does SciSparc offer online?
SciSparc's subsidiary sells hemp-based products like gummies, oils, capsules, and creams on Amazon Marketplace.
Where is SciSparc Ltd. based?
SciSparc Ltd. is based in Tel Aviv, Israel.
Is SciSparc involved in cancer research?
Yes, through its venture MitoCareX Bio, SciSparc is involved in cancer drug discovery targeting mitochondrial SLC25 proteins.
What patents has SciSparc recently secured?
SciSparc has recently secured patents in the U.S., Canada, and Europe for cannabinoid compositions and antimicrobial methods.
Who leads SciSparc Ltd.?
SciSparc Ltd. is led by a team of experienced senior executives and scientists.
What is SCI-210?
SCI-210 is a proprietary treatment combining cannabidiol (CBD) and CannAmide™ for Autism Spectrum Disorder and status epilepticus.
What is the significance of SciSparc's new patents?
The new patents strengthen SciSparc's intellectual property portfolio and enhance its position in the global pharmaceutical market.
SciSparc Ltd. Ordinary Shares